欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

休市中 12-19 16:08:06

8.170

+0.100

+1.24%

最高8.200	最低8.010	成交量76.30万
今开8.100	昨收8.070	日振幅2.35%
总市值66.59亿	流通市值66.59亿	总股本8.15亿
成交额620.72万	换手率0.09%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":8.17,"timestamp":1766131686003,"preClose":8.07,"halted":0,"volume":763000,"delay":0,"floatShares":815000000,"shares":815000000,"eps":-0.43397667567231085,"marketStatus":"休市中","change":0.1,"latestTime":"12-19 16:08:06","open":8.1,"high":8.2,"low":8.01,"amount":6207155,"amplitude":0.023544,"askPrice":8.18,"askSize":34000,"bidPrice":8.17,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":-0.36818395150647415,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":8.07,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":1.3143126056452838,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2592813296","title":"港股异动 | 森松国际(02155)现涨超8% 制药装备周期修复 公司为全球高端压力设备龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2592813296","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592813296?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:46","pubTimestamp":1766115972,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，森松国际现涨超8%，截至发稿，涨7.97%，报9.08港元，成交额2242.05万港元。开源证券发布研报称，森松国际作为全球高端压力设备龙头，受益制药行业CAPEX复苏及海外MNC扩产需求，新签订单快速增长，马来西亚二期产能释放缩短工程周期，叠加收购法玛度、比欧强化生物制药能力，“MVP”数智化解决方案驱动业绩高速增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","02155","BK1587","LU1171460220.USD","BK1183","BK1548","BK1191","BK1574"],"gpt_icon":0},{"id":"2592711132","title":"商务部发布2026年甘草及甘草制品出口配额公开招标投标企业名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2592711132","media":"北京日报客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592711132?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:45","pubTimestamp":1766115900,"startTime":"0","endTime":"0","summary":"转自：北京日报客户端根据商务部2025年第78号公告，经审核，现将2026年甘草及甘草制品出口配额公开招标投标企业名单发布如下：一、符合鲜或干的甘草投标资格的企业（76家）1.亳州市中药饮片厂2.安徽贺林中药饮片科技有限公司3.安徽和济堂中药饮片有限公司4.安徽谓博中药股份有限公司5.安徽省本草国药饮片有限公司6.安徽盛林国药饮片有限公司7.亳州市盛林中药饮片有限公司8.安徽省天和中药材开发有限公","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-19/doc-inhcicep7777788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","09939","BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2592903469","title":"歌礼制药-B(01672)12月18日斥资253.86万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903469","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592903469?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:17","pubTimestamp":1766060221,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月18日斥资253.86万港元回购20万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251218/31875436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01477","BK1191","BK1515","BK1574","BK1161","01672"],"gpt_icon":0},{"id":"2592970254","title":"今年港股最大Biotech IPO！英硅智能拟募资23亿港元冲刺AI制药第一股，AI制药能否完成全新药物研发再受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2592970254","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592970254?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:36","pubTimestamp":1766057772,"startTime":"0","endTime":"0","summary":"以每股24.05港元的发行价计算，英硅智能将通过本次IPO募集至多约23亿港元，IPO市值则将达134.06亿港元，英硅智能将成为今年港股市场最大Biotech IPO。AI+制药再次引发业内关注。据悉，英硅智能在上市前经历了多轮融资，累计融资逾5.30亿美元。截至2025年6月30日，英硅智能持有的现金及等价物由2024年末的约1.26亿美元增至约2.13亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1766053261341090403","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2592514974","title":"每日卖空追踪 | 歌礼制药-B 12月18日卖空量成交21.7万股，卖空比例为11.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592514974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592514974?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:30","pubTimestamp":1766046622,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间12月18日，跌3.81%，卖空量成交21.7万股，较上一交易日减少6.06%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163314a45aa164&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163314a45aa164&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","BK1191","01477","BK1161","01672"],"gpt_icon":0},{"id":"2592974571","title":"歌礼制药-B盘中异动 股价大跌5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974571","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592974571?lang=zh_cn&edition=full","pubTime":"2025-12-18 09:33","pubTimestamp":1766021597,"startTime":"0","endTime":"0","summary":"2025年12月18日早盘09时33分，歌礼制药-B股票出现异动，股价大幅下挫5.33%。截至发稿，该股报12.430港元/股，成交量9.6万股，换手率0.01%，振幅5.86%。歌礼制药-B股票所在的生物技术行业中，整体涨幅为1.33%。其相关个股中，科伦博泰生物-B、派格生物医药-B、基石药业-B涨幅较大，振幅较大的相关个股有歌礼制药-B、圣诺医药-B、拨康视云-B，振幅分别为5.26%、4.96%、4.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218093317953b66cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218093317953b66cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01672","BK1574","BK1515","01477","BK1191"],"gpt_icon":0},{"id":"2592910853","title":"欧康维视生物-B12月17日获主力加仓94.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592910853","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592910853?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:15","pubTimestamp":1765959355,"startTime":"0","endTime":"0","summary":"12月17日, 欧康维视生物-B股价涨1.37%，报收8.14元，成交金额340.9万元，换手率0.05%，振幅2.74%，量比0.54。欧康维视生物-B今日主力资金净流入94.5万元，上一交易日主力净流入25.8万元。该股近5个交易日下跌1.21%，主力资金累计净流入141.9万元；近20日主力资金累计净流出142.0万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217162149a45603b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217162149a45603b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2591989723","title":"歌礼制药-B(01672)12月16日斥资260.99万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591989723","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591989723?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:03","pubTimestamp":1765886631,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月16日斥资260.99万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","01672","BK1574","BK1191","BK1161","BK1515"],"gpt_icon":0},{"id":"2592361931","title":"每日卖空追踪 | 歌礼制药-B 12月16日卖空量成交12.5万股，卖空比例为1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592361931","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592361931?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:30","pubTimestamp":1765873821,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间12月16日，涨0.08%，卖空量成交12.5万股，较上一交易日减少37.81%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216163323a4519de5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216163323a4519de5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","BK1191","01477","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2591065596","title":"睿智医药“90后前主持人董秘”任职11天辞职，无制药行业和董秘经验引质疑，公司经历多次董事长更迭","url":"https://stock-news.laohu8.com/highlight/detail?id=2591065596","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591065596?lang=zh_cn&edition=full","pubTime":"2025-12-16 14:50","pubTimestamp":1765867834,"startTime":"0","endTime":"0","summary":"根据睿智医药12月1日的公告，许剑因工作调整原因，申请辞去公司董事会秘书职务，辞职报告自送达董事会之日起生效。许剑原定任期至公司第六届董事会届满为止。2021年3月17日，睿智医药公告称，胡瑞连被卷入其个人投资的吉林吉福参生物开发股份有限公司股权纠纷，涉嫌职务侵占，公安机关对其采取刑事拘留强制措施。2021年11月，随着胡瑞连的辞职，曾宪维正式当选为睿智医药董事长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765867536538846670","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0216","01477","BK1191","BK1574","300149","BK0077"],"gpt_icon":0},{"id":"2591867976","title":"港股异动 | 歌礼制药-B(01672)回暖近3% IL-17抑制剂ASC50美国I期研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2591867976","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591867976?lang=zh_cn&edition=full","pubTime":"2025-12-16 09:53","pubTimestamp":1765850029,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B回暖近3%，截至发稿，涨2.01%，报13.2港元，成交额3184.24万港元。消息面上，12月15日，歌礼制药-B发布公告，ASC50在美国开展的一项随机、双盲、安慰剂对照的I期临床试验取得积极顶线结果，该试验是在健康受试者中进行的单剂量递增研究，旨在评估ASC50的安全性、耐受性、药代动力学及外周循环的白细胞介素-17A靶向结合特征。46名健康受试者接受了10毫克、30毫克、100毫克、200毫克、400毫克或600毫克ASC50，或匹配的安慰剂给药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01672","BK1515","BK1161","01477","BK1191"],"gpt_icon":0},{"id":"2591625600","title":"3家药企因下游合作方“不合规交易行为”公开致歉","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625600","media":"一拾药讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591625600?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:35","pubTimestamp":1765791351,"startTime":"0","endTime":"0","summary":"近日，河南省医药集中采购平台公布了3家药企发布的致歉声明。分别为哈尔滨誉衡制药、吉林四环制药、珠海经济特区粤康医药三家企业的公开致歉声明，原因均为其配送商或代理商存在不合规交易行为。珠海经济特区粤康医药则因其注射用头孢呋辛钠的代理商违规，被预评为“特别严重失信”。这一现象反映出，在医药招采信用评价制度下，药企对合作方的合规管理已与其自身信用直接挂钩，下游一旦违规，药企也难逃责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215183743a44dbf01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215183743a44dbf01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","09939","BK1574","BK1191","BK1593","01477","BK1515","BK1161","00460"],"gpt_icon":0},{"id":"2591116096","title":"歌礼制药-B(01672)：有望成为同类最佳口服小分子IL-17抑制剂ASC50美国I期研究取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2591116096","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591116096?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:49","pubTimestamp":1765788597,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，ASC50在美国开展的一项随机、双盲、安慰剂对照的I期临床试验取得积极顶线结果，该试验是在健康受试者中进行的单剂量递增研究，旨在评估ASC50的安全性、耐受性、药代动力学及外周循环的白细胞介素-17A靶向结合特征。ASC50为歌礼自主研发的口服小分子IL-17靶向抑制剂，IL-17在银屑病等多种自身免疫及炎症性疾病中已获充分的生物学验证并具备成熟商业价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","BK1161","01672","01477","BK1515"],"gpt_icon":0},{"id":"2591956296","title":"港股开盘 | 恒指低开1% 医药板块跌幅居前 歌礼制药(01672)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591956296","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591956296?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:30","pubTimestamp":1765762255,"startTime":"0","endTime":"0","summary":"恒生指数低开1%，恒生科技指数跌1.34%。盘面上，辅助生殖概念活跃，三胎概念股锦欣生殖开涨约3%；医药板块跌幅居前，歌礼制药跌超5%。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215093112_33389.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215093112_33389.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f81ff915a0c110277ba56cf9ecd1a11a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["513600","HSI","BK1161","BK4614","BK1515","BK1574","MCHmain","MHImain","02833","01672","BK1191","YANG","HSImain","HHImain","09939","01477","159938"],"gpt_icon":0},{"id":"2590570816","title":"歌礼制药-B(01672)12月12日耗资约437.38万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590570816?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:21","pubTimestamp":1765534862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2025年12月12日耗资约437.38万港元回购30万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","BK1191","01672","BK1161","01477"],"gpt_icon":0},{"id":"2591687883","title":"近期，齐鲁制药、诺诚健华等在抗肿瘤药方面好消息频现！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591687883","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591687883?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:11","pubTimestamp":1765519893,"startTime":"0","endTime":"0","summary":"近些年来，中国抗肿瘤药物市场销售一直呈现稳步增长趋势。随着老龄化及公众癌症预防意识的持续提高，抗肿瘤药物市场规模还在不断上涨，业内预计到2029年，中国抗肿瘤药物行业市场规模有望达到5590亿元。近期，就有不少药企在新药临床、上市方面传来好消息。其通过瘤内注射，具有抑制肿瘤生长的功能。总的来说，2025年中国在抗肿瘤药方面的不断突破，是近年来医药行业转型升级的集中体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212141533a44414c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212141533a44414c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","BK1161","01477","09969"],"gpt_icon":0},{"id":"2590516019","title":"丹麦减肥药制造商Zealand公布雄心勃勃的2030年战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516019","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590516019?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:23","pubTimestamp":1765459380,"startTime":"0","endTime":"0","summary":"丹麦生物制药公司泽兰制药周四为其抗肥胖药物组合公布了一项雄心勃勃的五年战略，突显出随着更多此类药物即将上市，来自小型企业的竞争日益加剧，使市场领导者诺和诺德和礼来公司之间的竞争日趋激烈。　　这项名为“代谢前沿2030”的新战略出台之际，泽兰制药股价今年以来已下跌29%，因为投资者押注该市场将趋于分散，单一赢家的数量将少于18个月前减肥药热潮顶峰时期。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-11/doc-inhamxqc6406780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","BK4532","IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","BK4585","01477","BK4599","BK4588","BK4007","IE00BZ1G4Q59.USD","ZEAL","LU0154236417.USD"],"gpt_icon":1},{"id":"2590545341","title":"歌礼制药-B12月11日主力净流出132.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545341","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590545341?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:16","pubTimestamp":1765440965,"startTime":"0","endTime":"0","summary":"12月11日, 歌礼制药-B股价跌5.48%，报收15.00元，成交金额7920.3万元，换手率0.52%，振幅7.31%，量比0.40。歌礼制药-B今日主力资金净流出132.0万元，上一交易日主力净流入396.5万元。该股近5个交易日上涨16.20%，主力资金累计净流出3377.5万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入387.6万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162316a6990e12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162316a6990e12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","BK1191","01672","BK1515","BK1161"],"gpt_icon":0},{"id":"2590158116","title":"重药控股最新公告：参股子公司药友制药与辉瑞签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2590158116","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590158116?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:50","pubTimestamp":1765367412,"startTime":"0","endTime":"0","summary":"重药控股(000950.SZ)公告称，公司参股子公司药友制药与辉瑞签订许可协议，药友制药授予辉瑞在全球范围内及人类、动物所有适应症的治疗、诊断及预防领域独家开发、使用、生产及商业化口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂（包括YP05002）及含有该活性成分的产品。就本次许可，药友制药将有权依约获得（其中包括）不可退还的首付款 15,000万美元及基于许可产品临床、商业化进展获得开发里程碑付款至多35,000万美元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000035059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","000950","01477","BK0071","BK1191","BK0250"],"gpt_icon":0},{"id":"2590300641","title":"歌礼制药-B(01672)：同类首创FASN抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590300641","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590300641?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:06","pubTimestamp":1765357565,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，董事会宣布同类首创、每日一次口服小分子脂肪酸合成酶抑制剂地尼法司他治疗中重度寻常性痤疮的新药上市申请获中国国家药监局受理。地尼法司他显示出了良好的安全性与耐受性特征。未有观察到与地尼法司他 相关的永久性终止治疗或煺出试验的情况。公司已于近期完成与中国国家药监局就地尼法司他治疗中重度寻常性痤疮的新药上市申请前沟通并收到国家药监局的积极反馈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","01672","BK1574","01477","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":0.0062},{"period":"3month","weight":-0.0779},{"period":"6month","weight":-0.2219},{"period":"1year","weight":0.78},{"period":"ytd","weight":0.8156}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家控股公司，主要从事眼科治疗药物的研发和商业化。该公司主要产品包括OT-401 (YUTIQ)、OT-1001 (ZERVIATE)、OT-502 (DEXYCU)、OT-301 (NCX 470)、OT-101和OT-202等。该公司业务主要在国内市场开展。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.116968},{"month":2,"riseRate":0.4,"avgChangeRate":-0.049128},{"month":3,"riseRate":0.6,"avgChangeRate":0.058111},{"month":4,"riseRate":0.4,"avgChangeRate":0.017956},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.073739}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}